AstraZeneca

Neil Shastri-Hurst Excerpts

Monday 3rd February 2025 Commons Chamber

[Chris Bryant]

There are all sorts of bids coming in now, none of which I am in charge of, but we have seen significant added investments in the UK since the autumn. For instance, Iberdrola is doubling its investment through Scottish Power from £12 billion to £24 billion over the next four years, and Blackstone has confirmed a £10 billion investment in Blyth in Northumberland. What is essential, however, is for us to ensure that that investment stretches across the UK, that we have the skills we need in order to deliver those investments, and that we have the economic structures in place to enable them to remain, because they are long-term investments, not just short-term ones. Also, sometimes, we have to tackle the over-regulation that exists in some elements of the economy, particularly in relation to planning, so that we can get down to making the decisions that the Tories should have made for 14 years.

[Dr Neil Shastri-Hurst (Solihull West and Shirley) (Con)]

The chief scientific officer has previously stated the importance of this investment in the UK’s pandemic preparedness. In the light of the announcement, what assessment has the Minister made of the impact on the UK’s ability to respond to future pandemics?

[Chris Bryant]

It is not entirely dependent on our AstraZeneca programme, and indeed, as I have already pointed out, the piece of work in which it was intending to invest—I hope I will get the science right—was changing the way in which it would create the nasal flu vaccine for children from an egg-based to a cell-based system. It has now decided not to do that, but to stick to the egg-based system. I think that if the chief scientific adviser or the chief medical officer has anything on which to update the House, he and/or she will do so.